Pharma channel feed – Endpoints News

Pharma channel feed

Highlighting a major shift at the FDA, regulators put Amicus' once-spurned drug on fast track

8 years ago

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths

8 years ago

Bayer boosted as FDA OKs its PI3K drug Aliqopa for relapsed follicular lymphoma patients

8 years ago

FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche's Avastin

8 years ago

The FDA just unveiled its new, pricier fee schedule to review new drugs

8 years ago

Mustang ties the knot with Fred Hutch on next-gen CAR-T for lymphoma

8 years ago

Looking for an I/O edge, Bristol-Myers fronts $105M to partner with Halozyme as Roche expands pact

8 years ago

Otonomy brings out the ax after a catastrophic PhIII failure

8 years ago

Mylan attacks Allergan over its Mohawk-allied patent strategy — but the CEO is sticking to his guns

8 years ago

Scott Gottlieb is closing a big loophole in the orphan drug law

8 years ago

Alexion is reorganizing R&D, axing 600-plus jobs and moving HQ to Boston as execs prep deal spree

8 years ago

WATCH: Scott Gottlieb vows to shake up the FDA, backing a trend toward faster drug development

8 years ago

Struggling in R&D, GSK lines up an FDA pitch on COPD with mixed data

8 years ago

Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance

8 years ago

Following up on Trump's orders, the FDA wants to know: which regulations and paperwork requirements need to go?

8 years ago

Eli Lilly slashes R&D jobs, shutters 2 research sites as it looks to cut 3,500 staffers worldwide

8 years ago

Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug

8 years ago

Alnylam slammed after patient death forces investigators to halt dosing of fitusiran, raising new safety fears

8 years ago

Safety fears spur FDA to pause checkpoint combo studies by Bristol-Myers, Celgene

8 years ago

Sarepta readies FDA pitch after a small study spotlights 1% dystrophin add for golodirsen in Duchenne MD

8 years ago

Emboldened by recent R&D successes, Merck KGaA looks at selling off $1B-plus consumer division

8 years ago

Troubled Acorda hurries to bar the door against a takeover attempt

8 years ago

Neurotoxicity kills a CAR-T rival pushed by J&J, MacroGenics in $700M deal

8 years ago

Feds scoop up a band of biotech insiders who allegedly bagged a windfall, and now criminal charges

8 years ago

First page Previous page 314 315 316317318 319 320 Next page Last page